InMode has provided preliminary Q2 revenue guidance of $95.2M–$95.4M, ahead of analyst expectations and demonstrating continued demand for its Morpheus8 RF microneedling and fractional-laser systems. The guidance arrives amid the Steel Partners takeover bid and competing CEO-led buyout, underscoring the underlying strength of the energy-device market.
Market
InMode Guides Q2 Revenue to $95.2M–$95.4M — Growth Resilience Amid Takeover Uncertainty
InMode's preliminary Q2 revenue guidance exceeds consensus, signaling sustained demand for RF and fractional-laser platforms despite acquisition turmoil.
InMode guides Q2 revenue to $95.2M–$95.4M, signaling sustained demand for RF and fractional-laser platforms.
For practice owners, InMode's revenue resilience reflects sustained adoption of RF microneedling and fractional laser in medspa and surgical settings. The company's installed base and per-procedure pricing power remain intact despite competitive pressure from Cynosure, Cutera, and Lumenis. However, takeover uncertainty may delay new device placements and rebate negotiations; practices considering InMode capital equipment should clarify pricing and loyalty terms before deal closure, expected by year-end.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.